BJDX Logo

Bluejay Diagnostics, Inc. (BJDX) 

NASDAQ$2.64-4.86 (-64.80%)
Market Cap
$4.16M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
464 of 893
Rank in Industry
59 of 113

BJDX Insider Trading Activity

BJDX Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
Sells
$0
0

Related Transactions

About Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the …

Insider Activity of Bluejay Diagnostics, Inc.

Over the last 12 months, insiders at Bluejay Diagnostics, Inc. have bought $0 and sold $0 worth of Bluejay Diagnostics, Inc. stock.

On average, over the past 5 years, insiders at Bluejay Diagnostics, Inc. have bought $61,573 and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 500 shares for transaction amount of $1,635 was made by Dey Indranil (President and CEO) on 2023‑12‑13.

List of Insider Buy and Sell Transactions, Bluejay Diagnostics, Inc.

2023-12-13PurchaseDey IndranilPresident and CEO
500
0.044%
$3.27
$1,635
-85.64%
2023-12-13PurchaseDey Svetlanadirector
500
0.0413%
$3.07
$1,535
-85.64%
2023-03-28PurchaseDey IndranilPresident and CEO
2,000
0.0105%
$0.44
$880
-49.65%
2023-03-27PurchaseDey IndranilPresident and CEO
8,000
0.0393%
$0.44
$3,520
-53.01%
2023-03-24PurchaseDey Svetlanadirector
10,000
0.0502%
$0.44
$4,400
-51.67%
2022-08-26PurchaseFisher Kenneth RChief Financial Officer
20,000
0.0992%
$1.03
$20,600
-57.23%
2022-04-25PurchaseFisher Kenneth RChief Financial Officer
20,000
0.0943%
$0.99
$19,800
-21.74%
2022-03-17PurchaseWurth Douglas Clark
40,000
0.1983%
$1.18
$47,120
-24.35%
2022-03-17PurchaseKinder Gordon WinstonChief Financial Officer
2,500
0.0122%
$1.16
$2,898
-24.35%
2022-03-17PurchaseDey Svetlana
10,000
0.0498%
$1.18
$11,830
-24.35%
2022-03-16PurchaseWurth Douglas Clark
60,000
0.2823%
$1.09
$65,400
-20.91%
2022-03-14PurchaseKinder Gordon WinstonChief Financial Officer
5,000
0.0274%
$1.02
$5,100
+1.69%
Total: 12

BJDX Institutional Investors: Active Positions

Increased Positions5+27.78%2,456+12.08%
Decreased Positions9-50%18,952-93.24%
New Positions2New1,326New
Sold Out Positions9Sold Out18,952Sold Out
Total Postitions14-22.22%3,829-81.16%

BJDX Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Ubs Group Ag$7.000.2%1,945+716+58.26%2024-12-31
Cvi Holdings, Llc$5.000.13%1,323+1,323New2024-06-30
Tower Research Capital Llc (Trc)$2.000.06%554+411+287.41%2024-12-31
Bank Of America Corp /De/$00%4+3+300%2024-12-31
Osaic Holdings, Inc.$00%3+3New2024-12-31
Hrt Financial Lp$00%0-793Sold Out2024-12-31
Jump Financial, Llc$00%0-208Sold Out2024-12-31
Citadel Advisors Llc$00%0-1,044Sold Out2024-12-31
Anson Funds Management Lp$00%0-6,386Sold Out2024-12-31
Geode Capital Management, Llc$00%0-404Sold Out2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.